Table 1 Characteristics of patients in the training and validation sets
Variables | Training set (n = 347) | Validation set (n = 230) | P value |
|---|---|---|---|
Age (years) | 37.34 ± 9.76 | 38.62 ± 10.40 | 0.132 |
Male gender, n (%) | 220 (63.4%) | 138 (60%) | 0.410 |
WBC (× 109/ L) | 5.80 ± 1.48 | 5.87 ± 1.68 | 0.597 |
PLT (× 109/ L) | 187.00 (154.00–214.00) | 186.00 (148.00–217.25) | 0.882 |
TBIL (µmol/L) | 15.10 (12.30–18.60) | 14.30 (11.50–18.50) | 0.100 |
ALB (g/L) | 44.90 (42.90–46.90) | 44.40 (42.30–45.80) | 0.035 |
GLB (g/L) | 29.05 (26.88–32.03) | 29.45 (26.65–32.33) | 0.799 |
GGT (U/L) | 20.00 (15.00–30.00) | 20.50 (15.00–31.25) | 0.792 |
ALP (U/L) | 80.00 (65.00–93.00) | 79.00 (67.00–96.00) | 0.346 |
ALT (U/L) | 33.00 (22.00–50.00) | 32.00 (20.00–48.25) | 0.213 |
AST (U/L) | 28.00 (23.00–37.00) | 28.00 (22.00–36.00) | 0.348 |
HBeAg, Positive N (%) | 179 (51.6%) | 122 (53.0%) | 0.652 |
Necro-inflammatory active grade G0/G1/G2/G3/G4 | 4/164/149/30/0 | 5/112/89/23/1 | 0.451 |
Fibrosis stage S0/S1/S2/S3/S4 | 21/145/122/26/33 | 12/83/96/14/24 | 0.492 |
Anti-HBC (S/CO) | 10.27 (8.70–11.55) | 10.02 (8.79–11.22) | 0.348 |
HBV-DNA (IU/mL) | 69,500.00(2250.00–23,000,000.00) | 95,000.00(2200.00–17,000,000.00) | 0.972 |
G ≥ 2, N (%) | 179 (51.5%) | 113 (49.1%) | |
S ≥ 2, N (%) | 181 (52.2%) | 134 (58.2%) |